Business Context and Reporting Period
Company: Artelo Biosciences, Inc. (ARTL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Artelo is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system (ECS). Key programs include ART27.13 (cancer-related anorexia), ART26.12 (chemotherapy-induced peripheral neuropathy), and ART12.11 (CBD cocrystal). The company has incurred losses since inception and has not generated any revenue.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,120) | $(1,132) | $(8,713) | $(6,048) |
| Loss Per Share (Basic/Diluted) | $(3.97) | $(2.10) | $(12.48) | $(11.28) |
| Cash and Cash Equivalents (End of Period) | $1,720 | $4,357 | $1,720 | $4,357 |
| Working Capital | $(3,033) | $785 | $(3,033) | $785 |
| Total Debt (Convertible Notes) | $875 | $0 | $875 | $0 |
| Digital Assets (SOL) | $325 | $0 | $325 | $0 |
Note: All figures in thousands except per share data. Working capital is negative due to current liabilities exceeding current assets.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased significantly to $3.1 million in Q3 2025 from $1.2 million in Q3 2024. This was driven by higher professional fees related to capital raising and increased R&D expenditures for clinical programs. For the nine months ended September 30, 2025, expenses were $8.6 million compared to $6.3 million in the prior year.
- Net Loss: Net loss widened to $3.1 million in Q3 2025 from $1.1 million in Q3 2024. The nine-month loss increased to $8.7 million from $6.0 million.
- Liquidity: Cash and cash equivalents decreased from $2.3 million at year-end 2024 to $1.7 million at September 30, 2025. Net cash used in operating activities was $5.6 million for the nine months ended September 30, 2025.
- Capital Structure: The company issued $0.9 million in convertible notes in May 2025 and raised approximately $4.4 million in net proceeds from equity offerings (common stock and warrants) during the nine-month period. A 1-for-6 reverse stock split was effective in June 2025.
- Digital Assets: The company adopted ASU 2023-08 and purchased Solana (SOL) tokens with a cost basis of $250,000, recorded at a fair value of $325,000 as of September 30, 2025.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. The company requires additional funding to continue operations and has no assurance of success in raising capital.
- Clinical Progress:
- ART27.13: Interim results from the Phase 2a CAReS trial showed compelling weight gain (6.38% increase) in treated patients compared to placebo (-5.42% loss). Safety profile remains favorable.
- ART26.12: Completed Phase 1 Single Ascending Dose study in healthy volunteers with no drug-related adverse events observed.
- Financing Activities:
- On October 1, 2025 (subsequent event), the company closed an underwritten offering for gross proceeds of approximately $2.0 million.
- On October 28, 2025 (subsequent event), the company issued new convertible notes ($0.69 million principal) and warrants by converting existing notes.
- A planned $9.5 million PIPE transaction in August 2025 was terminated.
- Risks: Key risks include the inability to raise additional capital, volatility in digital asset valuations (SOL), dependence on clinical trial outcomes, and potential dilution from future equity issuances.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.7 million cash balance against the $8.7 million nine-month burn rate and upcoming clinical trial costs.
- Debt Obligations: Review the terms of the $0.9 million convertible notes (12% interest, 180-day maturity) and the subsequent October 2025 refinancing to assess immediate liquidity pressure.
- Digital Asset Exposure: Confirm the valuation methodology and risk management protocols for the $325,000 Solana (SOL) holding, which impacts net income volatility.
- Clinical Milestones: Monitor enrollment and data readouts for the ART27.13 Phase 2a trial and ART26.12 Phase 1b/2a progression.
- Dilution Impact: Assess the impact of recent and planned equity offerings (including the October 2025 offering) on existing shareholder ownership.